MCID: INF039
MIFTS: 43

Infratentorial Cancer

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Infratentorial Cancer

MalaCards integrated aliases for Infratentorial Cancer:

Name: Infratentorial Cancer 12 14 69
Infratentorial Neoplasms 42 69
Malignant Infratentorial Tumors 12
Brain Neoplasm, Infratentorial 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4706
ICD10 33 C71.7
MeSH 42 D015192
NCIt 47 C3139 C4966

Summaries for Infratentorial Cancer

Disease Ontology : 12 A brain cancer that is located in the infratentorial region.

MalaCards based summary : Infratentorial Cancer, also known as infratentorial neoplasms, is related to childhood infratentorial neoplasm and medulloblastoma. An important gene associated with Infratentorial Cancer is SHH (Sonic Hedgehog), and among its related pathways/superpathways are Signaling by Hedgehog and Pathways in cancer. The drugs Carboplatin and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and bone marrow, and related phenotypes are digestive/alimentary and behavior/neurological

Related Diseases for Infratentorial Cancer

Diseases related to Infratentorial Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 73)
id Related Disease Score Top Affiliating Genes
1 childhood infratentorial neoplasm 11.9
2 medulloblastoma 10.9
3 homocystinuria due to defect in methylation cbl g 10.7 GLI2 PTCH1
4 signet ring basal cell carcinoma 10.7 MYC PTCH1
5 sporadic pheochromocytoma 10.6 GLI2 PTCH1 SHH
6 celosomia 10.6 GLI2 PTCH1 SHH
7 laryngotracheoesophageal cleft type 2 10.6 GLI2 PTCH1 SHH
8 camptocormism 10.6 GLI2 PTCH1 TP53
9 laryngotracheoesophageal cleft type 4 10.6 GLI2 PTCH1 SHH
10 devriendt syndrome 10.6 MYCN SYP
11 isolated facial myokymia 10.6 GLI2 PTCH1 SHH
12 prostate embryonal rhabdomyosarcoma 10.6 GLI1 MYCN PTCH1
13 complement receptor deficiency 10.6 GLI2 OTX2
14 alopecia areata 1 10.6 GLI3 MYC SHH
15 c5 deficiency 10.6 GLI1 GLI2 SHH
16 macular dystrophy, patterned, 3 10.6 GLI2 PTCH1 SHH
17 pneumonia 10.5 GLI1 SHH SYP
18 classic variant of chromophobe renal cell carcinoma 10.5 GLI1 SHH SYP
19 glycogen storage disease due to lactate dehydrogenase deficiency 10.5 CTNNB1 TP53
20 pelizaeus-merzbacher disease in female carriers 10.5 GLI2 PTCH1 SHH SUFU
21 agnathia-otocephaly complex 10.5 GLI2 OTX2 SHH
22 prostate rhabdomyosarcoma 10.4 GLI1 MYCN PTCH1 TP53
23 atypical choroid plexus papilloma 10.4 IER3IP1 SMARCB1 TP53
24 oral antidiabetic drugs toxicity or dose selection 10.4 GLI1 PTCH1 SHH SUFU TP53
25 shwachman-diamond type metaphyseal dysplasia 10.4 GLI3 IER3IP1 SHH
26 pancreatic somatostatinoma 10.3 CTNNB1 GLI1 SHH TP53
27 immune system organ benign neoplasm 10.3 CTNNB1 SYP TP53
28 hypogonadotropic hypogonadism-retinitis pigmentosa syndrome 10.3 NES SYP TP53
29 polydactyly, preaxial, type iv 10.3 GLI1 GLI2 GLI3 SHH
30 hair disease 10.3 ATOH1 SUFU SYP TP53
31 extrinsic cardiomyopathy 10.3 ATOH1 SYP TP53
32 brain glioma 10.3 NES SYP TP53
33 paroxysmal nocturnal hemoglobinuria 10.3 CTNNB1 GLI1 SHH TP53
34 vulvar keratoacanthoma-like carcinoma 10.3 MYC MYCN SYP TP53
35 imperforate anus 10.3 GLI2 GLI3 MYCN SHH
36 postmenopausal atrophic vaginitis 10.3 MYC MYCN SYP TP53
37 cystadenoma 10.3 MYC MYCN SYP TP53
38 benign shuddering attacks 10.3 PTCH1 SYP TP53
39 hydrocephalus 10.3 GLI2 PTCH1 SHH
40 vestibular disease 10.3 NES SYP TP53
41 transitional cell cancer of the renal pelvis and ureter 10.3 GLI3 MYCN SHH SYP
42 trachea squamous cell carcinoma 10.2 CTNNB1 MYC TP53
43 cervical adenomyoma 10.2 NES SYP TP53
44 gliofibroma 10.2 SMARCB1 SYP TP53
45 male reproductive organ benign neoplasm 10.2 CTNNB1 SYP TP53
46 peritoneal benign neoplasm 10.2 SMARCB1 SYP TP53
47 breast myoepithelial neoplasm 10.2 CTNNB1 TP53
48 bardet-biedl syndrome 10.2 CTNNB1 MYC TP53
49 childhood choroid plexus cancer 10.1 IER3IP1 SMARCB1 SYP TP53
50 brachial plexus neuritis 10.1 IER3IP1 SMARCB1 SYP TP53

Graphical network of the top 20 diseases related to Infratentorial Cancer:



Diseases related to Infratentorial Cancer

Symptoms & Phenotypes for Infratentorial Cancer

MGI Mouse Phenotypes related to Infratentorial Cancer:

44 (show all 24)
id Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.44 SHH SMARCB1 SUFU TP53 ATOH1 CTNNB1
2 behavior/neurological MP:0005386 10.43 ATOH1 CTNNB1 GLI1 GLI2 MYC MYCN
3 growth/size/body region MP:0005378 10.41 CTNNB1 GLI1 GLI2 GLI3 MYC MYCN
4 mortality/aging MP:0010768 10.4 MYCN NTRK3 OTX2 PPP1R12A PTCH1 SHH
5 cardiovascular system MP:0005385 10.39 CTNNB1 GLI3 MYC MYCN NTRK3 OTX2
6 cellular MP:0005384 10.38 MYCN OTX2 PTCH1 SHH SMARCB1 TP53
7 embryo MP:0005380 10.36 CTNNB1 GLI1 GLI2 GLI3 MYC MYCN
8 nervous system MP:0003631 10.35 GLI2 GLI3 MYC MYCN NTRK3 OTX2
9 craniofacial MP:0005382 10.34 MYC MYCN OTX2 PTCH1 SHH SUFU
10 normal MP:0002873 10.28 ATOH1 CTNNB1 GLI1 GLI2 GLI3 MYC
11 endocrine/exocrine gland MP:0005379 10.27 ATOH1 CTNNB1 GLI1 GLI2 GLI3 MYC
12 limbs/digits/tail MP:0005371 10.24 MYCN PTCH1 SHH SUFU TP53 CTNNB1
13 no phenotypic analysis MP:0003012 10.23 SUFU TP53 ATOH1 CTNNB1 GLI1 GLI2
14 hearing/vestibular/ear MP:0005377 10.21 ATOH1 CTNNB1 GLI2 GLI3 MYC NTRK3
15 muscle MP:0005369 10.21 MYCN OTX2 PPP1R12A PTCH1 SHH SMARCB1
16 integument MP:0010771 10.2 ATOH1 CTNNB1 GLI2 GLI3 MYC PTCH1
17 neoplasm MP:0002006 10.1 SUFU TP53 CTNNB1 GLI1 MYC PTCH1
18 reproductive system MP:0005389 10.06 GLI3 MYC MYCN OTX2 PTCH1 SHH
19 respiratory system MP:0005388 10.03 ATOH1 CTNNB1 GLI1 GLI2 GLI3 MYCN
20 renal/urinary system MP:0005367 9.97 CTNNB1 GLI1 GLI3 MYCN PPP1R12A PTCH1
21 pigmentation MP:0001186 9.95 CTNNB1 GLI3 MYC OTX2 PTCH1 SUFU
22 skeleton MP:0005390 9.85 CTNNB1 GLI2 GLI3 MYC MYCN OTX2
23 vision/eye MP:0005391 9.36 CTNNB1 GLI2 GLI3 MYCN NTRK3 OTX2
24 taste/olfaction MP:0005394 9.26 CTNNB1 GLI3 OTX2 SHH

Drugs & Therapeutics for Infratentorial Cancer

Drugs for Infratentorial Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 191)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
2
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
3
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
4
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
5
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
6
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
7
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1 85622-93-1 5394
8 Thiotepa Approved Phase 3,Phase 2,Phase 1 52-24-4 5453
9
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
10
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
11
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
12
Ondansetron Approved Phase 3 99614-02-5 4595
13
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
14
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
16
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
17 Alkylating Agents Phase 3,Phase 2,Phase 1
18 Antimetabolites Phase 3,Phase 2
19 Antimetabolites, Antineoplastic Phase 3,Phase 2
20 Antimitotic Agents Phase 3,Phase 2,Phase 1
21 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
22 Antirheumatic Agents Phase 3,Phase 2,Phase 1
23 Dermatologic Agents Phase 3,Phase 2,Phase 1
24 Etoposide phosphate Phase 3,Phase 2,Phase 1
25 Folic Acid Antagonists Phase 3,Phase 2
26 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
27 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
28 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
29 Vitamin B Complex Phase 3,Phase 2
30 Antiemetics Phase 3,Phase 1
31 Autonomic Agents Phase 3,Phase 1
32 BB 1101 Phase 3,Phase 2,Phase 1
33 Dexamethasone acetate Phase 3,Phase 2,Phase 1 1177-87-3
34 Emetics Phase 3
35 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
36 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
37 Anti-Allergic Agents Phase 3,Phase 2
38 Antipruritics Phase 3,Phase 2
39 Histamine Antagonists Phase 3,Phase 2
40 Histamine H1 Antagonists Phase 3,Phase 2
41
Histamine Phosphate Phase 3,Phase 2 51-74-1 65513
42 Neurotransmitter Agents Phase 3,Phase 2,Phase 1
43
Serotonin Phase 3,Phase 2 50-67-9 5202
44 Serotonin Agents Phase 3,Phase 2
45 Serotonin Antagonists Phase 3,Phase 2
46 Folate Nutraceutical Phase 3,Phase 2
47 Vitamin B9 Nutraceutical Phase 3,Phase 2
48
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
49
Irinotecan Approved, Investigational Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
50
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4

Interventional clinical trials:

(show top 50) (show all 83)

id Name Status NCT ID Phase Drugs
1 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
2 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
3 Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma Recruiting NCT01096368 Phase 3 liposomal vincristine sulfate;carboplatin;cyclophosphamide;etoposide;cisplatin
4 Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy Active, not recruiting NCT00683319 Phase 3 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
5 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
6 Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma Unknown status NCT00826241 Phase 2 Temozolomide;Lapatinib
7 Etoposide in Treating Young Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2 etoposide
8 High-Dose Methotrexate in Treating Young Patients With Residual Ependymoma Unknown status NCT00287924 Phase 2 methotrexate
9 Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
10 Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma Completed NCT00004224 Phase 2 cyclophosphamide;etoposide;vincristine sulfate
11 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
12 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
13 Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors Completed NCT00002463 Phase 2 MOPP Regimen;Leucovorin Calcium;Mechlorethamine Hydrochloride;Methotrexate;Prednisone;Procarbazine Hydrochloride;Vincristine Sulfate
14 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
15 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin
16 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
17 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
18 Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors Completed NCT00005955 Phase 2 temozolomide
19 Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
20 Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Completed NCT01462695 Phase 2 Sunitinib Malate
21 The Effects of Scalp Block on Haemodynamic Response and Postoperative Pain in Posterior Fossa Surgery Completed NCT02852382 Phase 2 Bupivacaine;morphine patient controlled analgesia
22 Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors Completed NCT01836549 Phase 2 imetelstat sodium
23 Carboplatin and Bevacizumab for Recurrent Ependymoma Recruiting NCT01295944 Phase 2 Carboplatin;Bevacizumab
24 A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma Recruiting NCT01878617 Phase 2 Cyclophosphamide;Cisplatin;Vincristine;Vismodegib;Pemetrexed;Gemcitabine
25 Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children Recruiting NCT02672241 Phase 2 Nimotuzumab;Temozolomide
26 Efficacy of Acetaminophen in Posterior Fossa Surgery Recruiting NCT02532322 Phase 2 IV acetaminophen;normal saline
27 Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma Active, not recruiting NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
28 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
29 Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting NCT00939770 Phase 1, Phase 2 crizotinib
30 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
31 External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas Active, not recruiting NCT01012609 Phase 2
32 A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma Active, not recruiting NCT01390948 Phase 2 Bevacizumab;Temozolomide (TMZ)
33 Stereotactic Radiotherapy of the Resection Cavity of Brain Metastases vs. Post-operative Whole-brain Radiotherapy Not yet recruiting NCT03285932 Phase 2
34 Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor Withdrawn NCT00003273 Phase 2 carboplatin;cisplatin;cyclophosphamide;etoposide;leucovorin calcium;methotrexate;temozolomide;thiotepa;vincristine sulfate
35 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
36 Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma Unknown status NCT00360854 Phase 1 erlotinib hydrochloride
37 FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Completed NCT00053963 Phase 1 romidepsin
38 Cilengitide in Treating Children With Refractory Primary Brain Tumors Completed NCT00063973 Phase 1 cilengitide
39 Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma Completed NCT00363272 Phase 1 ispinesib
40 Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Completed NCT00100880 Phase 1 lenalidomide
41 Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Completed NCT00052780 Phase 1 O6-benzylguanine;temozolomide
42 ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Completed NCT00946335 Phase 1 veliparib;temozolomide
43 AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors Completed NCT00326664 Phase 1 Cediranib Maleate
44 VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors Completed NCT00098761 Phase 1 laromustine
45 Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer Completed NCT00003022 Phase 1
46 Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors Completed NCT00107458 Phase 1 valproic acid
47 Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Completed NCT01076530 Phase 1 vorinostat;temozolomide
48 Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors Completed NCT00003141 Phase 1 carboplatin;cisplatin;cyclophosphamide;etoposide;thiotepa;vincristine sulfate
49 Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor Completed NCT00069940 Phase 1
50 Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors Completed NCT00503724 Phase 1 enzastaurin hydrochloride

Search NIH Clinical Center for Infratentorial Cancer

Cochrane evidence based reviews: infratentorial neoplasms

Genetic Tests for Infratentorial Cancer

Anatomical Context for Infratentorial Cancer

MalaCards organs/tissues related to Infratentorial Cancer:

39
Brain, Bone, Bone Marrow, Spinal Cord, T Cells, Nk Cells, Testes

Publications for Infratentorial Cancer

Variations for Infratentorial Cancer

Expression for Infratentorial Cancer

Search GEO for disease gene expression data for Infratentorial Cancer.

Pathways for Infratentorial Cancer

Pathways related to Infratentorial Cancer according to GeneCards Suite gene sharing:

(show all 21)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.45 GLI1 GLI2 GLI3 PTCH1 SHH SUFU
2 12.21 CTNNB1 GLI1 GLI2 GLI3 MYC PTCH1
3
Show member pathways
12.18 GLI1 GLI3 PPP1R12A PTCH1
4 12.15 CTNNB1 MYC PPP1R12A PTCH1 SHH TP53
5 12 CTNNB1 GLI3 MYC SHH
6 11.99 CTNNB1 GLI1 GLI2 PTCH1 SHH SUFU
7 11.95 MYC NES OTX2 SHH
8 11.84 CTNNB1 MED27 MYC TP53
9
Show member pathways
11.74 GLI1 GLI2 GLI3 PTCH1 SHH SUFU
10 11.68 NES SHH SYP
11 11.58 MYC MYCN TP53
12
Show member pathways
11.58 CTNNB1 GLI1 GLI2 GLI3 PTCH1 SHH
13 11.56 MYC NTRK3 TP53
14 11.3 GLI1 GLI2 PTCH1 SHH
15 11.2 CTNNB1 MYC TP53
16
Show member pathways
11.15 GLI2 PTCH1 SHH
17 11.1 GLI1 GLI2 OTX2 SHH
18
Show member pathways
10.98 MYC OTX2 TP53
19 10.55 GLI3 SHH
20 10.46 PTCH1 SHH
21 10.25 MYC MYCN

GO Terms for Infratentorial Cancer

Cellular components related to Infratentorial Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleolus GO:0005730 9.8 GLI2 MED27 MYC MYCN SMARCB1 TP53
2 cilium GO:0005929 9.55 GLI1 GLI2 GLI3 PTCH1 SUFU
3 axoneme GO:0005930 9.43 GLI1 GLI2 GLI3
4 ciliary tip GO:0097542 9.26 GLI1 GLI2 GLI3 SUFU
5 ciliary base GO:0097546 8.92 GLI1 GLI2 GLI3 SUFU

Biological processes related to Infratentorial Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 84)
id Name GO ID Score Top Affiliating Genes
1 kidney development GO:0001822 9.99 CTNNB1 GLI2 GLI3 SHH
2 canonical Wnt signaling pathway GO:0060070 9.97 CTNNB1 GLI1 MYC SHH
3 forebrain development GO:0030900 9.95 CTNNB1 GLI3 OTX2 SHH
4 positive regulation of neuron differentiation GO:0045666 9.93 ATOH1 GLI2 KCTD11
5 cellular response to drug GO:0035690 9.93 MYC PPP1R12A TP53
6 odontogenesis of dentin-containing tooth GO:0042475 9.93 CTNNB1 GLI2 GLI3 SHH
7 smoothened signaling pathway GO:0007224 9.93 GLI1 GLI2 GLI3 PTCH1 SHH
8 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.93 ATOH1 CTNNB1 GLI1 GLI2 GLI3 MYC
9 negative regulation of cell differentiation GO:0045596 9.92 CTNNB1 GLI3 SHH
10 pattern specification process GO:0007389 9.92 GLI2 GLI3 PTCH1 SHH
11 embryonic limb morphogenesis GO:0030326 9.91 GLI3 PTCH1 SHH
12 inner ear development GO:0048839 9.91 ATOH1 GLI3 SHH
13 skin development GO:0043588 9.9 CTNNB1 SHH SUFU
14 limb development GO:0060173 9.9 CTNNB1 GLI3 SHH
15 midbrain development GO:0030901 9.9 CTNNB1 OTX2 SHH
16 positive regulation of mesenchymal cell proliferation GO:0002053 9.9 CTNNB1 MYC MYCN SHH
17 embryonic organ development GO:0048568 9.89 GLI3 PTCH1 SHH
18 mammary gland development GO:0030879 9.89 GLI2 GLI3 PTCH1
19 branching morphogenesis of an epithelial tube GO:0048754 9.89 GLI2 GLI3 MYCN SHH
20 developmental growth GO:0048589 9.87 GLI2 GLI3 SHH
21 T cell differentiation in thymus GO:0033077 9.87 CTNNB1 GLI3 SHH
22 proximal/distal pattern formation GO:0009954 9.86 CTNNB1 GLI1 GLI2 GLI3
23 hindbrain development GO:0030902 9.85 CTNNB1 GLI2 SHH
24 renal system development GO:0072001 9.85 CTNNB1 PTCH1 SHH
25 positive regulation of neuroblast proliferation GO:0002052 9.85 CTNNB1 GLI3 SHH
26 regulation of smoothened signaling pathway GO:0008589 9.85 GLI1 GLI2 OTX2 PTCH1
27 lung development GO:0030324 9.85 CTNNB1 GLI1 GLI2 GLI3 MYCN SHH
28 anatomical structure formation involved in morphogenesis GO:0048646 9.83 GLI2 GLI3 SHH
29 negative regulation of smoothened signaling pathway GO:0045879 9.83 GLI3 KCTD11 PTCH1 SUFU
30 embryonic digit morphogenesis GO:0042733 9.83 CTNNB1 GLI2 GLI3 MYCN SHH
31 anatomical structure development GO:0048856 9.82 GLI2 GLI3 SHH
32 dorsal/ventral neural tube patterning GO:0021904 9.81 GLI2 PTCH1 SHH
33 spinal cord motor neuron differentiation GO:0021522 9.81 GLI2 GLI3 PTCH1 SHH
34 branching involved in ureteric bud morphogenesis GO:0001658 9.8 CTNNB1 GLI3 MYC PTCH1 SHH
35 smoothened signaling pathway involved in dorsal/ventral neural tube patterning GO:0060831 9.79 GLI2 GLI3 PTCH1
36 regulation of osteoblast differentiation GO:0045667 9.76 CTNNB1 GLI1
37 ectoderm development GO:0007398 9.76 CTNNB1 SHH
38 layer formation in cerebral cortex GO:0021819 9.76 CTNNB1 GLI3
39 negative regulation of astrocyte differentiation GO:0048712 9.76 MYCN NTRK3
40 negative thymic T cell selection GO:0045060 9.76 GLI3 SHH
41 lung-associated mesenchyme development GO:0060484 9.75 CTNNB1 SHH
42 embryonic foregut morphogenesis GO:0048617 9.75 CTNNB1 SHH
43 positive regulation of alpha-beta T cell differentiation GO:0046638 9.75 GLI3 SHH
44 positive regulation of T cell differentiation in thymus GO:0033089 9.75 GLI2 SHH
45 positive regulation of skeletal muscle tissue development GO:0048643 9.75 CTNNB1 SHH
46 smoothened signaling pathway involved in regulation of cerebellar granule cell precursor cell proliferation GO:0021938 9.75 GLI1 GLI2 SHH
47 artery development GO:0060840 9.74 GLI3 SHH
48 negative regulation of cell division GO:0051782 9.74 MYC PTCH1
49 hindgut morphogenesis GO:0007442 9.74 GLI2 GLI3 SHH
50 mammary gland duct morphogenesis GO:0060603 9.73 GLI2 PTCH1

Molecular functions related to Infratentorial Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.96 ATOH1 CTNNB1 GLI1 GLI2 GLI3 MYC
2 chromatin binding GO:0003682 9.77 CTNNB1 GLI1 GLI2 GLI3 TP53
3 transcription regulatory region DNA binding GO:0044212 9.76 CTNNB1 GLI1 GLI2 TP53
4 transcription factor activity, sequence-specific DNA binding GO:0003700 9.76 ATOH1 CTNNB1 GLI2 GLI3 MYC MYCN
5 transcription factor binding GO:0008134 9.72 CTNNB1 GLI2 MYC SUFU TP53
6 p53 binding GO:0002039 9.61 NTRK3 SMARCB1 TP53
7 patched binding GO:0005113 9.4 PTCH1 SHH
8 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001077 9.35 ATOH1 GLI2 GLI3 MYC OTX2
9 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000978 9.23 ATOH1 CTNNB1 GLI1 GLI2 GLI3 MYC

Sources for Infratentorial Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....